Android app Apple app link

Prostate cancer drug now available to more patients with aggressive form of disease

By Fox News   |   5 days ago
Prostate cancer drug now available to more patients with aggressive form of disease

Novartis expands approval for prostate cancer drug, Pluvicto, offering hope to mCRPC patients. The targeted radioligand therapy shows promising results in delaying disease progression and reducing risk of death. Novartis plans to explore RLT use for other advanced cancers.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.